Phase 3 Readout~month

Phase 3 Topline: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versu

Drug
day101
Indication
Low-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma

Other upcoming events for DAWN

Patent ExpiryPatent/Exclusivity Expiry: OJEMDA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versu — DAWN Phase 3 Readout | BioSniper